How to buy Neuronetics stock | $4.94

Neuronetics Inc is a diagnostics & research business based in the US. Neuronetics shares (STIM) are listed on the NASDAQ and all prices are listed in US Dollars. Neuronetics employs 161 staff and has a trailing 12-month revenue of around 0.00.

Neuronetics stock price (NASDAQ: STIM)

Use our graph to track the performance of STIM stocks over time.

Neuronetics shares at a glance

• Key figures

Information last updated 2021-10-09.

Latest market close	$4.94
52-week range	$4.78 - $22.43
50-day moving average	$6.82
200-day moving average	$11.51
Wall St. target price	$17.50
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.03

Buy Neuronetics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Neuronetics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Neuronetics price performance over time

Historical closes compared with the close of $4.94 from 2021-10-14

1 week (2021-10-08)	-22.93%
1 month (2021-09-16)	-24.00%
3 months (2021-07-16)	-63.68%
6 months (2021-04-16)	-57.04%

1 year (2020-10-16)	-20.96%
2 years (2019-10-16)	-44.24%
3 years (2018-10-16)	24.19
5 years (2016-10-12)	N/A

Neuronetics financials

Revenue TTM	$54.5 million
Gross profit TTM	$37.7 million
Return on assets TTM	-9.18%
Return on equity TTM	-35.51%
Profit margin	-41.24%
Book value	$3.71
Market capitalisation	$168.7 million

TTM: trailing 12 months

Shorting Neuronetics shares

There are currently 1.9 million Neuronetics shares held short by investors – that's known as Neuronetics's "short interest". This figure is 11.9% down from 2.1 million last month.

There are a few different ways that this level of interest in shorting Neuronetics shares can be evaluated.

Neuronetics's "short interest ratio" (SIR)

Neuronetics's "short interest ratio" (SIR) is the quantity of Neuronetics shares currently shorted divided by the average quantity of Neuronetics shares traded daily (recently around 472046.96969697). Neuronetics's SIR currently stands at 3.96. In other words for every 100,000 Neuronetics shares traded daily on the market, roughly 3960 shares are currently held short.

However Neuronetics's short interest can also be evaluated against the total number of Neuronetics shares, or, against the total number of tradable Neuronetics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Neuronetics's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Neuronetics shares in existence, roughly 70 shares are currently held short) or 0.0778% of the tradable shares (for every 100,000 tradable Neuronetics shares, roughly 78 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Neuronetics.

Find out more about how you can short Neuronetics stock.

Neuronetics share dividends

We're not expecting Neuronetics to pay a dividend over the next 12 months.

Neuronetics share price volatility

Over the last 12 months, Neuronetics's shares have ranged in value from as little as $4.78 up to $22.43. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Neuronetics's is 2.4929. This would suggest that Neuronetics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Neuronetics overview

Neuronetics, Inc. , a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2003 and is headquartered in Malvern, Pennsylvania.

Frequently asked questions

What percentage of Neuronetics is owned by insiders or institutions?
Currently 6.856% of Neuronetics shares are held by insiders and 91.682% by institutions. How many people work for Neuronetics?
Latest data suggests 161 work at Neuronetics. When does the fiscal year end for Neuronetics?
Neuronetics's fiscal year ends in December. Where is Neuronetics based?
Neuronetics's address is: 3222 Phoenixville Pike, Malvern, PA, United States, 19355 What is Neuronetics's ISIN number?
Neuronetics's international securities identification number is: US64131A1051 What is Neuronetics's CUSIP number?
Neuronetics's Committee on Uniform Securities Identification Procedures number is: 64131A105